News

Examining why newly registered trials have fallen in Central and Eastern Europe, relative to other regions.

Survey sheds light on the regional-specific risks of managing clinical trial sites in Eastern Europe.

Study uncovers subtle distinctions in attitudes and perceptions among the two groups.

EMA expects a small rise in the pre-authorization activities for human medicines in 2016. Around 546 requests for scientific advice are anticipated, compared to 510 in 2015.

Managed by EMA on behalf of the EU medicines regulatory network, EudraVigilance receives over one million adverse drug reaction reports per year.

Boehringer Ingelheim will integrate Medidata’s study planning, data management, data analytics and RBM capabilities into multiple stages of its drug development process.

Many of the most problematic provisions for health research were eased by amendments that provided exemptions from the overall constraints.

The sponsors will use CRF Health's TrialMax® platform to support data capture for quality of life issues during the post-progression phase.

The December Forum included discussions of global disclosure performance, and highlighted the importance of measuring disclosure performance.

The solution identifies unknown relationships in data, whereby customers can perform dimension-free exploratory analysis on data such as adverse events, labs, concomitant medications, medical history and vital signs.

Bracket SMS allows for reminders to be sent direct to patient mobile phones when they've opted in to the service.

Find out the latest appointments and more in the clinical trials industry.

According to Target Health, this is the first product to be approved using for in its pivotal trial, direct data entry of patient data at the time of the clinic visit into an EDC system, with no need for paper records.

Patient involvement, transparency, and support for innovative medicines are among the key objectives of the European Medicines Agency (EMA) over the next five years, according to Executive Director Prof. Guido Rasi.

Potential assets that could benefit from this new offering include small molecule drugs, biologics, medical devices, combination therapies and novel technologies.

Scientists plan to use the funds to repurpose Artesunate, an antimalarial drug discovered by Nobel Prize Laureate (2015) in a clinical trial aimed at cutting the rate of metastases in colorectal cancer.

ICON is using Activate for all global studies, which span more than 50 countries.

Nextrials CEO James Rogers believes with renewed focus on eSource driven by the FDA and industry standards groups like CDISC, sponsor companies and sites will take advantage of EHR systems to streamline clinical research.